Latest news
Serological Biomarkers in Primary Sclerosing Cholangitis (PSC): Focus on anti-GP2 IgA
Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease affecting the bile ducts and often leading to fibrosis, cirrhosis, and eventually liver failure. PSC also carries an increased risk of hepatobiliary malignancies, particularly cholangiocarcinoma. Despite significant research efforts, PSC remains difficult to diagnose and manage because its pathogenesis is not fully understood and reliable disease-specific biomarkers are still lacking1. Recent advances in serological biomarker research, however, are beginning to improve our understanding of the disease and may support better clinical management.
The Need for Biomarkers in PSC
The diagnosis of PSC typically relies on imaging techniques such as magnetic resonance cholangiopancreatography (MRCP), revealing characteristic bile duct abnormalities. Laboratories commonly use markers such as alkaline phosphatase (ALP) to monitor disease activity. However, ALP levels fluctuate significantly and therefore provide limited value for predicting prognosis in individual patients.
Because PSC shows highly variable clinical course, identifying biomarkers that help stratify patients according to disease severity and progression risk is a major clinical need. These interactions likely play a key role in the development of PSC. Finding reliable serological biomarkers in PSC is a major focus of current research2.
The Role of anti-GP2 IgA Autoantibodies in PSC
More recently, attention has shifted toward IgA-type antibodies because of their key role in mucosal immunity. Immune interactions along the gut–liver axis strongly influence PSC, and IgA-mediated responses play a significant role in disease progression.
Among the currently investigated biomarkers, anti-GP2 IgA has emerged as one of the most promising serological markers for risk stratification in PSC. Multiple studies have demonstrated that the presence of anti-GP2 IgA correlates with a more severe disease phenotype and a significantly higher risk of developing end-stage liver disease requiring transplantation. In addition, anti-GP2 IgA positivity has been associated with an increased risk of cholangiocarcinoma in PSC patients3456.
Pancreatic glycoprotein 2 (GP2) is a membrane protein expressed on pancreatic acinar cells and on specialized intestinal M cells, where it plays a role in mucosal immune defense and bacterial antigen recognition. Because GP2 participates in gut immune surveillance, immune responses directed against this protein may reflect disturbances in the gut–liver axis that are characteristic of PSC.
Another IgA-based marker, IgA anti-F-actin antibodies, also correlates with progressive disease and enhanced mucosal immune responses. These findings further support the hypothesis that disrupted gut–liver immune signaling is a central feature of PSC pathogenesis.
Additional Immunological Biomarkers
Immune-mediated processes play a central role in PSC, and researchers have investigated several immunoglobulin-related biomarkers.
Elevated serum IgG4 levels are found in approximately 10% of PSC patients and are associated with more severe disease and shorter transplantation-free survival. Although the exact mechanisms remain unclear, IgG4 elevation appears to identify a subgroup of patients with more aggressive disease progression7.
Another commonly observed marker is atypical perinuclear anti-neutrophil cytoplasmic antibodies (pANCA)8. These antibodies are detected in a large proportion of PSC patients, but they lack disease specificity because they can also appear in other autoimmune conditions. PR3-ANCA were found in PSC patient with cholangiocarcinoma9. Nevertheless, their presence may reflect abnormal immune responses triggered by microbial antigens originating from the gut.
(->Discover how new technology can help in the identification of ANCA pattern)
Emerging Biomarkers
Beyond autoantibodies, various inflammatory and fibrosis-related biomarkers are under investigation. For example, studies link elevated levels of interleukin-8, macrophage activation markers such as soluble CD163, and extracellular matrix remodeling markers to worse clinical outcomes. However, most of these markers still require further clinical validation.
Future Perspectives
Although PSC still lacks a single disease-specific diagnostic marker, the growing body of research on serological biomarkers is improving our ability to understand disease mechanisms and identify high-risk patient subgroups. Among the currently investigated markers, anti-GP2 IgA represents one of the most promising candidates for clinical application in risk stratification and disease monitoring.
Continued research into these biomarkers may not only enhance clinical decision-making but also reveal novel therapeutic targets for this challenging disease.
Note: For laboratories interested in implementing anti-GP2 antibody testing, Medipan & GA Generic Assays offer validated ELISA kits that detect anti-GP2 IgA and IgG.
Related Product
| 3750 – Anti-GP2 IgA | Enzyme immunoassay for the quantitative determination of IgA antibodies against glycoprotein 2 (GP2) |
References
- Dyson et al., (2018) Primary sclerosing cholangitis ↩︎
- Tornai et al., (2022) Serological biomarkers for management of primary sclerosing cholangitis ↩︎
- Jendrek et al., (2017) Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis ↩︎
- Tornai et al., (2018) Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis ↩︎
- Sowa et al., (2018) Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype ↩︎
- Wunsch et al., (2021) Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis ↩︎
- Björnsson et al., (2011) Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy ↩︎
- Sebode et al., (2018) Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance ↩︎
- Wunsch et al., (2021) Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis ↩︎